Novartis to present early stage data on 19 investigational compounds at AACR annual meeting

Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research (AACR), April 5-9, 2014 in San Diego, CA. The AACR annual meeting highlights basic, translational and clinical discoveries in oncology. The investigational compounds featured in these Novartis studies are directed at multiple molecular targets and pathways. Currently Novartis Oncology is exploring more than 30 targets involved in cancer.

“Our research approach is driven by an understanding of cancers on a genomic level and developing therapies directed at those targets,” said Alessandro Riva, President, Novartis Oncology ad interim and Global Head, Oncology Development and Medical Affairs. “The AACR presentations demonstrate the depth and breadth of our pipeline, which allows us to test various combinations at an early stage to target different pathways and mutations involved in cancer.”

Among the data being presented are single agent and combination studies with key investigational compounds in the Novartis Oncology breast cancer development program, including an early phase study of the CDK4/6 inhibitor LEE011 and PI3K inhibitors BKM120 and BYL719. LEE011 and BKM120 are currently in Phase III and BYL719 is in Phase I trials for the treatment of advanced breast cancer.

In addition, preclinical data on ALK-inhibitor LDK378 (ceritinib) in ALK-positive non-small cell lung cancer (NSCLC) will be presented at the meeting. LDK378 was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) in 2013 and is currently under review by the FDA.

Early data will be presented on three additional investigational compounds including BGJ398, a highly specific fibroblast growth factor receptor (FGFR) inhibitor that Novartis is exploring in a variety of FGFR-driven solid tumors. A Phase I study of BGJ398 provides the first clinical evidence of activity against cancers that are driven by dysregulation of the FGFR pathway. In addition, the first data on CGM097, a selective p53-Mdm2 inhibitor currently under evaluation in Phase I trials in patients with p53 wild type tumors, and EGF816, a mutant-selective third generation EGFR inhibitor that is entering Phase I trials, will be presented.

More than 50 abstracts involving Novartis investigational compounds will be presented at AACR, including:

LEE011/BMK120/BYL719

• In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer (Abstract #4756; April 8, 4:05 p.m.)

BYL719

• Loss of PTEN leads to clinical resistance to the PI3K inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure (Abstract #LB327; April 8, 3:50 p.m.; this abstract will also be presented as part of the official AACR press briefing on April 8 at 7:30 a.m.)

LDK378

• The ALK inhibitor LDK378 overcomes crizotinib resistance in non-small cell lung cancer (Abstract #957; April 6, 4:05 p.m.)
• Combination CDK4/6 and ALK inhibition demonstrates on-target synergy against neuroblastoma (Abstract #1000; April 6, 4:35 p.m.)
• The Mdm2 inhibitor NVP-CGM097 enhances the anti-tumor activity of NVP-LDK378 in ALK mutant neuroblastoma models (Abstract #2929; April 7, 4:35 p.m.)

BGJ398

• Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors (Abstract #CT326; April 8, 10:50 a.m.; this abstract will also be presented as part of the official AACR press briefing on April 8 at 7:30 a.m.)

CGM097

• Pre-clinical characterization and clinical development of NVP-CGM097, a highly selective and optimized small-molecule inhibitor of p53-Mdm2 protein-protein interaction (Abstract #ED37-01; April 5, 3:15 p.m.)
• Discovery of NVP-CGM097 as a novel Mdm2 inhibitor (Abstract #DDT01-01; April 6, 1:00 p.m.)
• A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models (Abstract #2909; April 7, 3:00 p.m.)
• The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma (Abstract #5466; April 9, 8:00 a.m.)

EGF816

• EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC (Abstract #1733; April 7, 2014, 8:00 a.m.)
• In vitro characterization of EGF816, a third-generation mutant-selective EGFR inhibitor (Abstract #1734; April 7, 8:00 a.m.)